 The FDA has accepted Seelos Therapeutics Incs NASDAQ: SEEL Investigation New Drug application to study SLS-005 trehalose injection, 90.5 mgmL for spinocerebellar Ataxia SCA. The FDA has also granted the program Fast Track designation for SCA, and SLS-005 has previously received Orphan Drug designation for spinocerebellar ataxia type 3 SCA3 from the FDA and the European Medicines Agency. 